Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 153 Lung Neoplasms 73 Pancreatic Neoplasms 44 Neoplasms 27 Neoplasm Metastasis 25 Head and Neck Neoplasms 23 Brain Neoplasms 21 Breast Neoplasms 18 Glioblastoma 15 Adenocarcinoma of Lung 15 Squamous Cell Carcinoma of Head and Neck 14 Gliosarcoma 14 Adenocarcinoma, Bronchiolo-Alveolar 11 Colorectal Neoplasms 10 Glioma 9 Carcinoma, Squamous Cell 8 Carcinoma, Hepatocellular 8 Adenocarcinoma 7 Rectal Neoplasms 6 Prostatic Neoplasms 6 Esophageal Neoplasms 6 Central Nervous System Neoplasms 6 Carcinoma, Renal Cell 6 Astrocytoma 6 Oligodendroglioma 5 Liver Neoplasms 5 Colonic Neoplasms 5 Carcinoma 5 Recurrence 4 Ovarian Neoplasms 4

Interventions

Fulvestrant 2 ruxolitinib 1 dexpanthenol 1 ceterizine hydrochloride 1 capivasertib 1 benralizumab 1 Triamcinolone Acetonide 1 Tetracycline 1 Provitamins 1 Prednisone 1 Minocycline 1 Loperamide 1 Interviews as Topic 1 Hydrocortisone 1 HIV Testing 1 Gels 1 Fibroblast Growth Factor 7 1 Erlotinib Hydrochloride 1 Doxycycline 1 Dapsone 1 Clindamycin 1 Cetuximab 1 Anti-Bacterial Agents 1 Alpelisib 1 Acitretin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Exanthema × Erlotinib Hydrochloride × Clear all

NCT00473083 2017-04-04

LUTRAERL

British Columbia Cancer Agency

Phase 2 Completed

150 enrolled 13 charts

Exanthema, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡